von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.
about
Quantitative proteomics identifies the Myb-binding protein p160 as a novel target of the von Hippel-Lindau tumor suppressorVHL type 2B mutations retain VBC complex form and functionFIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activityA yeast two-hybrid system reconstituting substrate recognition of the von Hippel-Lindau tumor suppressor proteinThe von Hippel-Lindau tumor suppressor stabilizes novel plant homeodomain protein Jade-1NEDD8 acts as a 'molecular switch' defining the functional selectivity of VHLvon Hippel-Lindau disease: a clinical and scientific reviewState of the science: an update on renal cell carcinomaThe VHL tumor suppressor: master regulator of HIFpVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growthOxygen-sensing mechanisms and the regulation of redox-responsive transcription factors in development and pathophysiologyA common polymorphism in the oxygen-dependent degradation (ODD) domain of hypoxia inducible factor-1alpha (HIF-1alpha) does not impair Pro-564 hydroxylationGenetic analysis of pathways regulated by the von Hippel-Lindau tumor suppressor in Caenorhabditis elegansA HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomasReview: the Contribution of both Nature and Nurture to Carcinogenesis and Progression in Solid TumoursBuilding and remodelling Cullin-RING E3 ubiquitin ligasesHypoxia-inducible factor-1-mediated expression of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) gene. Its possible role in the Warburg effectGene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paragangliomaA comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma modelsInactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice.The role of PHD2 mutations in the pathogenesis of erythrocytosis.Deubiquitinases (DUBs) and DUB inhibitors: a patent reviewGenotype-phenotype correlations in Chinese von Hippel-Lindau disease patients.Deciphering von Hippel-Lindau (VHL/Vhl)-associated pancreatic manifestations by inactivating Vhl in specific pancreatic cell populations.Differences in regulation of tight junctions and cell morphology between VHL mutations from disease subtypes.Pathogenicity of DNA variants and double mutations in multiple endocrine neoplasia type 2 and von Hippel-Lindau syndrome.Molecular markers of paragangliomas/pheochromocytomasParagangliomas/Pheochromocytomas: clinically oriented genetic testingMutations of von Hippel-Lindau tumor-suppressor gene and congenital polycythemia.Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growthDrosophila von Hippel-Lindau tumor suppressor gene function in epithelial tubule morphogenesisMutation analysis of HIF prolyl hydroxylases (PHD/EGLN) in individuals with features of phaeochromocytoma and renal cell carcinoma susceptibilityMolecular imaging of hypoxia-inducible factor 1 alpha and von Hippel-Lindau interaction in miceProteomic dissection of the von Hippel-Lindau (VHL) interactome.VHL, the story of a tumour suppressor gene.Metastatic paraganglioma.Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL.Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells.The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing.
P2860
Q21135547-DF2D6BBA-B8BD-483E-A375-898F2B03FCE3Q21144205-BAD1B3BB-F472-46AC-BB1D-F1390F749B02Q24291819-A0FDBB3C-A524-4601-88D9-93B0CFC7A75FQ24299850-5F747661-F1E4-48F3-A099-0523A0C59ECFQ24304165-1DA0C4AD-BDDC-4E2D-BDFB-662F21CE8BD7Q24321579-4BC36118-6CC5-4625-A3DB-9C5E0A503A3EQ24622030-B2545E6C-EDE5-47A5-BF42-8358A1AA8F66Q24630685-1C34379D-9AA0-440F-B5E0-031F5909A7B8Q24634592-B9C13FC6-61C3-4781-887D-C8C51D1F3FE6Q24684757-91DB2834-4806-4432-BF92-A3308DD7C486Q24800550-63E26A96-B87A-4BD3-9FDC-BF8E0A6078D7Q24802444-20E95E11-B987-4679-88B7-280FC6AD74C1Q24802803-84CEEEDB-C731-42AA-A764-75D22096F681Q24804603-809792CC-4C2F-4921-9FD4-738ED3E445D0Q24811594-8BEA9919-22BE-4021-9671-24D2AC80AE05Q26749322-9800F0EC-358B-4882-8A5A-04D9EF45CDE2Q27027816-E005436E-14B1-4631-B2E5-3805DA3DC156Q28211384-71AC8983-46B3-4797-B373-D4057F86C01EQ28366764-13B259AA-A77B-4606-B12F-A45FF5F58274Q28485220-FBA7E18B-3134-42C4-AF26-D94D2DC4505CQ28590550-84E396F0-1C0B-4D3E-9D8B-0871ED886983Q28598099-57F0A1BB-822B-4DA6-AD72-6DB3C3FB072AQ28834608-37AEE7B0-29C0-4863-ACE8-62BA540CE839Q30252701-610FBA6F-778A-4C0A-AA73-5A862F136541Q33425920-26FA8046-EC97-49CD-BFE0-FF0E4F19F026Q33481999-4CAC4B4A-8508-493F-867F-754C9C715437Q33586709-409A9A0A-13A2-417B-8385-35D768DFE4BBQ33649025-D44C7EAF-28D6-4787-88E7-544DB0ED955BQ33679204-83E4F8E2-5A87-48E4-A7F3-C1EA3DCF901AQ33905244-D03778AE-AB33-4EC6-8B3A-48914AC3A486Q33998089-113922DD-2C6C-4E7B-A08C-14A72499B367Q34045653-9C2D5FF4-3C62-4CE9-8E18-5A33279CA47FQ34144574-0E47E7D3-F5A2-4D4D-BCA7-1D39BF28FC58Q34149009-948E3BAA-9780-4B7D-BDB2-91B8272CF312Q34218966-593FA502-87A9-41B9-8217-700046B54A4BQ34455226-24610C63-BBCE-40EE-A5A0-B1B8EE558478Q34480015-A772B363-103E-414F-8F82-BF023A5E0F1FQ34530199-09908C2E-0DA0-4935-ADAF-26E96AFAFCC3Q34536583-064C0F47-2A23-4EA4-B38A-00985BD9C92EQ34569380-0A2E04D5-E580-49D9-B41A-8EC0CBCD424C
P2860
von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
von Hippel-Lindau protein muta ...... e ability to downregulate HIF.
@ast
von Hippel-Lindau protein muta ...... e ability to downregulate HIF.
@en
von Hippel-Lindau protein muta ...... e ability to downregulate HIF.
@nl
type
label
von Hippel-Lindau protein muta ...... e ability to downregulate HIF.
@ast
von Hippel-Lindau protein muta ...... e ability to downregulate HIF.
@en
von Hippel-Lindau protein muta ...... e ability to downregulate HIF.
@nl
prefLabel
von Hippel-Lindau protein muta ...... e ability to downregulate HIF.
@ast
von Hippel-Lindau protein muta ...... e ability to downregulate HIF.
@en
von Hippel-Lindau protein muta ...... e ability to downregulate HIF.
@nl
P2093
P356
P1476
von Hippel-Lindau protein muta ...... e ability to downregulate HIF.
@en
P2093
P304
P356
10.1093/HMG/10.10.1019
P577
2001-05-01T00:00:00Z